Evidence map›Paper›PMID 34040364›Full record

ArticleClinical interventions in aging2021

Systemic Immune-Inflammation Index Predicts 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis.

Yiyun Weng, Tian Zeng, Honghao Huang, Junli Ren, Jianing Wang, Chenguang Yang, Wenjing Pan, Jingyu Hu, Fangyue Sun, Xinbo Zhou and 5 more

Abstract read
In one paragraph

Article in Clinical interventions in aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yiyun Weng *Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
Tian Zeng *School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Honghao Huang *School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Junli RenSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Jianing WangSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Chenguang YangSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Wenjing PanSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Jingyu HuSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Fangyue SunSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Xinbo ZhouSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Haojie QiuSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Yufan GaoSchool of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
Beibei GaoDepartment of Internal Medicine, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
Lifen ChiDepartment of Neurology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
Guangyong ChenDepartment of Neurology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.ORCID 0000-0003-1818-6280

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeSystemic immune-inflammation index (SII), a novel inflammation index derived from counts of circulating platelets, neutrophils and lymphocytes, has been studied in developing incident cancer. However, the clinical value of SII in acute ischemic stroke (AIS) patients had not been further investigated. Therefore, we aimed to explore the association between SII and severity of stroke as well as 3-month outcome of AIS patients.

methodsA total of 216 AIS patients receiving intravenous thrombolysis (IVT) and 875 healthy controls (HCs) were retrospectively recruited. Blood samples were collected within 24h after admission. Severity of stroke was assessed by the National Institute of Health stroke scale (NIHSS) scores on admission and poor 3-month functional outcome was defined as Modified Rankin Scale (mRS) > 2.

resultsSII levels in AIS patients were higher than in HCs. The cut-off value of SII is 545.14×10

conclusionSII is correlated with stroke severity at admission and can be a novel prognostic biomarker for AIS patients treated with IVT.

Indexed as

Administration, IntravenousAgedBrain IschemiaCase-Control StudiesHumansIschemic StrokeMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeTissue Plasminogen Activatorinflammationischemic strokeprognosissystemic immune-inflammation index

Identifiers

PMID34040364
PMCPMC8143961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.